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The generation of affinity reagents to large numbers of human proteins depends on the ability to express
the target proteins as high-quality antigens. The Structural Genomics Consortium (SGC) focuses on the
production and structure determination of human proteins. In a 7-year period, the SGC has deposited
crystal structures of >800 human protein domains, and has additionally expressed and purified a similar
number of protein domains that have not yet been crystallised. The targets include a diversity of protein
domains, with an attempt to provide high coverage of protein families. The family approach provides an
excellent basis for characterising the selectivity of affinity reagents. We present a summary of the
approaches used to generate purified human proteins or protein domains, a test case demonstrating the
ability to rapidly generate new proteins, and an optimisation study on the modification of >70 proteins
by biotinylation in vivo. These results provide a unique synergy between large-scale structural projects
and the recent efforts to produce a wide coverage of affinity reagents to the human proteome.Introduction
Antibodies and other affinity reagents are an invaluable resource
in investigating the function and distribution of proteins in
addition to potential therapeutic use. Considerable efforts are
being made to expand the spectrum of human proteins for which
validated and selective antibodies are available. Ideally a variety
of antibodies to a specific target protein should include molecules
suitable for different uses, including detection in ELISA and
Western blots, immunofluorescent imaging, sandwich assays,
immunoprecipitation and co-crystallisation, as well as modulat-
ing the activity of target molecules in a biological context. The
provision of high-quality antigens is crucial to this purpose.Corresponding author: Gileadi, O. (opher.gileadi@sgc.ox.ac.uk)
3 Pfizer Health AB, Mariefredsva¨gen 37, Box 108, 645 22 Stra¨ngna¨s, Sweden.
4 Current address: Structural Genomics Consortium, University of Toronto,
101 College Street, MaRS South Tower, Toronto, Ontario M5G 1L7, Canada.
1871-6784    doi:10.1016/j.nbt.2011.10.007  2011 Elsevier B.V. Open access under CC BY license.While short peptides may be best for eliciting antibodies to
specific post-translation modifications, a better variety of anti-
bodies are likely to be generated to larger protein fragments. The
use of recombinant Protein Epitope Signature Tags (PrESTs),
which are informatically derived fragments (50–150 amino acids)
of human proteins, has allowed the construction of vast antigen
and antibody libraries [1,2]. It has been argued that well-folded
protein domains can serve as better antigens for some purposes,
but this point has not been systematically explored. The provision
of a large variety of such folded domains in the context of
systematic affinity-reagent generating projects may shed light
on these issues.
Production and characterisation of stable domains from a wide
variety of proteins have been at the core of large-scale structural
genomics projects. Consequently, two by-products of these pro-
jects are large collections of recombinant human protein domains
(mostly preserved as expression clones and detailed protocols forwww.elsevier.com/locate/nbt 515
RESEARCH PAPER New Biotechnology  Volume 29, Number 5  June 2012
R
esearch
P
ap
erexpression and purification), as well as a set of methodologies for
dissecting and producing new protein domains.
This report presents three aspects of the production of human
protein domains. First, the existing bank of purified proteins and a
summary of the methods used to obtain these proteins. Second, a
description of a pilot study aimed at producing soluble domains of
a set of proteins selected without regard to feasibility or prior
knowledge. Finally, we present an extensive study on in vivo
protein biotinylation, an important step in preparing proteins
for immobilisation in procedures such as panning and Surface
Plasmon Resonance (SPR).
Materials and methods
Plasmids and strains
pNIC-Bio3 and pNIC-Bio2 are kanamycin-resistance vectors that
express fusion proteins with N-terminal histidine tags (His6 and
His10, respectively) followed by a TEV protease cleavage site, and a
C-terminal biotin acceptor site. pNIC28-Bsa4 and pNIC-H102 are
identical to pNIC-Bio3 and pNIC-Bio2 respectively, but lack the C-
terminal tag. All vectors are suitable for ligation-independent
cloning as described [3]; more vector details are provided in Fig. 1.
The Escherichia coli BirA gene, encoding biotin-protein ligase,
was cloned into plasmid pCDF-DUET1 (Novagen; spectinomycin-
resistance), creating the plasmid pCDF-BirA.
The expression host strain BL21(DE3)-R3-pRARE2 is a phage T1-
resistant strain bearing a plasmid (pRARE2; chloramphenicol-resis-
tance) that provides rare-codon tRNAs [3]. This strain was trans-
formed with pCDF-LIC and colonies were selected on media
containing chloramphenicol (34 mg/ml) and spectinomycin
(50 mg/ml) to create the strain Rosetta-R3-BirA, which was used
as host in biotinylation experiments.FIGURE 1
Plasmids used in biotinylation experiments. (a) pNIC28-Bsa4. (b) pNIC-Bio3. (c) The a
sequence of N- and C-terminal tags. *The cleavage site for TEV protease. (K^) ind
516 www.elsevier.com/locate/nbtThe plasmid sequences have been deposited with the following
accession numbers: pNIC-Bio2 (GenBank ID: JF912191), pNIC-
Bio3 (GenBank ID: JN792439), pNIC-H102 (GenBank ID:
JF912192), pNIC28-Bsa4 (GenBank ID: EF198106) and pCDF-BirA
(GenBank ID: JF914075).
Overview of protein production methods
The methods used for cloning, protein expression and purification
are summarised briefly here; full details have been published
(intracellular proteins [3,4]; secreted proteins in bacteria [5] and
baculovirus [6]).
Multiple constructs of every target gene were cloned in parallel
as PCR fragments, using ligation-independent cloning (LIC). The
cloning vectors for E. coli included fusion tags for affinity purifica-
tion, typically N-terminal His6 tags that can be cleaved with
Tobacco Etch Virus (TEV) protease. After clone verification, the
plasmids were used to transform an expression strain, typically a
derivative of Rosetta2 (a BL21 derivative harbouring the plasmid
pRARE2 that provides 7 rare-codon tRNAs; Novagen). All clones
were tested in small-scale cultures in rich medium (TB or LB), and
protein expression was induced by IPTG or arabinose at low
temperatures (15–258C). The recombinant proteins were then
purified from clarified lysates by immobilised metal affinity chro-
matography (IMAC) in batch, and the eluted proteins were
detected by SDS-PAGE and Coomassie blue staining. Selected
clones were grown and induced to a larger scale (0.75–6 L) and
the proteins were purified by protocols including IMAC, gel filtra-
tion and for some proteins tag cleavage and additional steps as
indicated. Proteins were analyzed by SDS-PAGE, mass spectro-
metry and other biophysical or biochemical means as indicated.
Variations of this basic procedure include the use of differentccessory plasmid, pCDF-BirA. (d) Plasmid information: GenBank accession IDs,
icates the lysine residue that is modified with biotin.
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TABLE 1
Distribution of human protein structures determined at the SGC
Target area Number of proteins
Protein kinase 89
Oxidoreductase 87
Transferase 78
Ubiquitilation 65
Miscellaneous 55
G-protein regulator 45
GTPase 43
Linker-PDZ 37
Nucleotide metabolism 34
Phosphatase 32
Methyl-lysine reader 28
Bromodomain 25
Non-protein kinase 21
RNA and DNA helicases 15
aa metabolic enzymes 13
Hydrolase-other 13
Isomerase 13
Protease 13
Cytoskeleton 12
PARP 11
BTB-Kelch 10
Lipid signalling-other 10
GTPase-RAS 9
Metabolic-NonDR 9
Other-signal 9
PI signalling – lipid binding domains 9
ATPases – Hsp70 6
GPCR-extracellular domains 6
WD40 6
Apoptosis-inflammation domains 4
Cytochrome P450 4
Lyase-carbonic-anhydrase 4
Macro domain 4
SOCS-box-containing 4
All structures of distinct human proteins or domains were divided into biochemical areas,
defined either by structural similarity or involvement in biological processes. The larger
groups may encompass highly diverse proteins. A full list of structures including
experimental procedures is provided on-line at www.thesgc.org/structures.
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doxin tags [3], or biotin acceptor peptides (this study) and the use
of bacterial secretion vectors inducible with arabinose, with pro-
teins purified from the culture medium [5].
Small-scale expression tests of biotinylated proteins
Rapid, high-throughput tests for production of soluble recombi-
nant proteins were performed using 1-ml bacterial cultures in 96
deep-well plates by a modification of an earlier method [3]. Cells
were grown at 378C in TB containing kanamycin and spectino-
mycin as described. When the culture turbidity reached 1–3, the
temperature was reduced to 188C. After 30 min, protein expression
was induced by adding IPTG (0.1 mM) and biotin (50 or 100 mM, as
indicated). Following overnight incubation, the cultures were
centrifuged and the supernatant was discarded. The cell pellets
could be stored frozen at 808C or processed directly. The pellets
were thoroughly suspended in 250 ml of lysis buffer comprising
100 mM HEPES, pH 8.0, 500 mM NaCl, 10% glycerol, 10 mM
imidazole, 1 mg/ml lysozyme, 0.1% n-dodecyl b-D-maltoside
(DDM), 1 mM MgSO4, 0.5 mM Tris(2-carboxyethyl)phosphine
(TCEP), Benzonase (Merck; 0.5 unit/ml) and protease inhibitors
(Calbiochem cocktail VI, 1:1000 dilution). The blocks were placed
at 808C for at least 20 min, then thawed in a water bath at room
temperature for 10–15 min. The suspensions were mixed in a
shaker at 700 rpm to effect complete lysis. The blocks were cen-
trifuged at 3500  g for 10 min. Meanwhile, Ni-NTA agarose was
aliquoted (50 ml of a 50% suspension in lysis buffer) into wells of a
96-well filter plate (1.2 mm, Millipore). The clarified supernatants
were transferred into the wells of the filter plate; the plate was
sealed at the top and mixed for 30 min on a shaker at 400 rpm,
188C. The liquid was then removed by vacuum filtration, taking
care not to dry the beads. The beads were washed three times by
adding 250 ml of wash buffer (20 mM HEPES, 500 mM NaCl,
25 mM imidazole, 10% glycerol and 0.5 mM TCEP) and vacuum
filtration.
The filter plate was placed on top of a waste block (96 deep-well
block) and centrifuged for 2 min at 300  g to remove the remain-
ing wash buffer. The bound proteins were then eluted by adding
40 ml of elution buffer (20 mM HEPES, pH 7.5, 500 mM NaCl,
500 mM imidazole, 10% glycerol and 0.5 mM TCEP) and mixing
for 20 min at 188C. The filter plate was placed on top of a 96-well
microtiter plate and the eluates were collected by centrifugation
(300  g, 3 min). The eluted proteins were analyzed by SDS-PAGE
and mass spectrometry as described previously [3,7].
Expression and purification of biotin-tagged SH2 domains
Large-scale expression was performed in a custom-made expres-
sion system (LEX) (Harbinger Biotech). In this system, E. coli cells
are cultivated in 1.5 L of medium in common 2 L glass bottles.
Filtered air is bubbled through the medium at a typical rate of 4–
6 L/min and thus the cultivations are both aerated and stirred. The
temperature is regulated by a thermostat-controlled water bath.
Inoculation cultures (20 ml) were started from glycerol stocks in
TB in 100 ml Erlenmeyer flasks supplemented with kanamycin
(100 mg/ml) and chloramphenicol (34 mg/ml). The cultures were
incubated overnight at 308C with shaking at 175 rpm. The follow-
ing morning, bottles with 1.5 L of TB supplemented with kana-
mycin (50 mg/ml) and 500 mL Antifoam 204 (anti-foam agent,Sigma) were inoculated with the starter cultures. The cultures were
incubated at 378C until OD600 reached 2. The temperature was
then reduced to 188C and protein production was induced by the
addition of 0.5 mM IPTG and 50–100 mM biotin. Protein expres-
sion was continued for approximately 20 h. Cells were harvested
by centrifugation at 4500  g for 10 min, resuspended in approxi-
mately 50 ml binding buffer (50 mM Na-phosphate, 500 mM
NaCl, 10% glycerol, 10 mM imidazole, 0.5 mM TCEP, pH 7.5)
supplemented with protease inhibitors, (Complete EDTA-free, 1
tablet/100 ml) and then stored in a freezer at 808C.www.elsevier.com/locate/nbt 517
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Benzonase (2000 U) was added. The suspensions were diluted in
lysis buffer to approximately 100 ml before sonication (6 min, 80%
amplitude, 4 s/4 s pulsing on a Sonics VibraCell) followed by
centrifugation at 49,000  g for 20 min. The supernatants were
filtered (0.45 mm) and applied to a two-step purification proce-
dure, IMAC and gel filtration, on an A¨KTA Xpress system (GE
Healthcare). Briefly, the lysates were loaded onto a 1 ml HiTrap
Chelating HP column (GE Healthcare) loaded with Ni2+ ions, at
0.8 ml/min. The immobilised proteins were washed first with
binding buffer until stable baselines were obtained, and then with
wash buffer (50 mM Na-phosphate, 500 mM NaCl, 10% glycerol,
25 mM imidazole, 0.5 mM TCEP, pH 7.5) for 20 column volumes
(CV) before elution with elution buffer (50 mM Na-phosphate,
500 mM NaCl, 10% glycerol, 500 mM imidazole, 0.5 mM TCEP,
pH 7.5) for 7.5 CV. The eluted proteins were collected and stored in
a loop on the system, reinjected onto a gel filtration column
(HiLoad Superdex 75 or 200, GE Healthcare) and finally eluted
in PBS buffer (10 mM Na-phosphate, 154 mM NaCl, 0.5 mM TCEP,FIGURE 2
Overview of expression and purification statistics (SGC-Oxford, 2004–2009). (a) Pi
(proteins) that were tested; targets which showed production of soluble protein in s
targets that generated diffracting crystals; initial models; and finished structures. (b)
baculovirus vetors and expressed in insect cells. The bars denote the same data as in
used for the proteins that crystallised successfully. Full-length proteins include those
1–2 residues from either end). The large tags (GST or Trx) were cleaved before crysta
TEV-Ni: IMAC and gel filtration, followed by cleavage of the His6 tag and removal 
include a diversity of chromatographic methods.
518 www.elsevier.com/locate/nbtpH 7.5) at 1.2 ml/min. Peaks were collected in 2 ml fractions in a
deep-well plate and analyzed by SDS-PAGE (Novex NuPAGE 4-12%
BisTris 17w gels, Invitrogen). Relevant fractions were pooled and
protein concentration was assessed by measuring the absorbance
at 280 nm on a Nanodrop ND-1000 (NanoDrop Technologies)
spectrophotometer. In case peaks corresponding to different mul-
timeric states were observed in the gel filtration step, these were
pooled separately. Samples from each protein batch were analyzed
by electrospray ionisation mass spectrometry (ESI-MS) according
to the protocol described in [8] to check the extent of the bioti-
nylation reaction.
Results and discussion
Protein production and crystallisation at the SGC
The SGC has solved and deposited structures of more than 841
distinct human protein domains [9]; a similar number of other
proteins have been purified but not yet crystallised (data not shown).
All proteins were produced in recombinant cells, most commonly
in E. coli but in some cases (3–4%) in baculovirus-infected insectpeline of targets tested in E. coli. The bars represent the number of targets
mall scale test expression; targets that were purified from large-scale culture;
 Targets that failed to express as soluble proteins in E. coli were subcloned into
 (a). (c) Summary of the characteristics of constructs and purification schemes
 with ‘trivial’ truncations (deletion of membrane-spanning, targeting signals or
llisation. Purification schemes: Ni – IMAC purification. GF – gel filtration. Ni-GF-
of contaminating proteins be re-binding to the IMAC resin. Additional steps
New Biotechnology Volume 29, Number 5  June 2012 RESEARCH PAPER
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used to produce and crystallise these proteins have been published
[3,10]. The structures represent a highly diverse selection of proteins
with a variety of metabolic, regulatory and structural functions.
A rough division of the solved targets is shown in Table 1. We
have attempted to cover multiple members of protein or domain
families, aiming both to provide insights on biological specificity
[11–18] and to build expertise in selected areas. A consequence of the
family-based approach is the availability of sets of related protein
domains that can be used to test the selectivity of affinity reagents
[4,19,20].
Production of soluble recombinant proteins in both E. coli and
baculovirus-infected insect cells relied on the following process:
(1) Bioinformatic analysis of the protein sequence, to predict
soluble domains and their boundaries.
(2) Parallel cloning of multiple fragments, designated by the
informatics analysis, into one or more expression vectors. On
average, 3–5 boundaries are tested at the ends of each protein
domain, resulting in 9–15 fragments. However, the number ofTABLE 2
Expression of soluble domains of newly introduced targets
Target gene/Uniprot ID Soluble constructs/tested 
N-His C-His His/Trx Baculo
AMPH/P49418 5/7 5/8 4/8 8/8 
CNO/Q9NUP1 2/7 0/9 5/7 3/7 
ETV1/P50549 5/8 0 7/7 7/7 
HCK (SH2-SH3)/P08631 6/8 2/8 5/8 4/7 
HMHA1/Q8IYN3 3/13 (weak) 1/12 5/13 
INADL/Q8NI35 3/5 1/6 2/5 4/5 
MSX2/P35548 5/8 2/9 7/8 3/8 
RBM3/P98179 6/6 5/6 6/6 6/6 
RCC1/P18754 0/1 1/1 1/1 1/1 
TEX9/Q8N6V9 0/3 2/4 (weak) (weak) 
PLEKHH1/Q9ULM0 0/16 0/16 4/16 ND 
HCK (kinase)/P08631 0/4 ND 5/6 (weak) 
Secreted proteins
Target gene E. coli Baculo
SPON1/Q9HCB6 1/3 1/6 Spondin_N 
CST3/P01034 1/1 1/1 Cystatin do
FAT3/Q8TDW7-3 11/24 ND Cadherin 32
EGF_like (aa
ITGB5/P18084 ND (weak) ND 
For each target and vector, the number of constructs expressing soluble proteins is listed, out o
protein included in a construct that was selected for scale-up and purification. N-His, C-His, T
baculovirus transfer vector pFB-LIC-Bse [4].constructs used for each target protein may be considerably
larger, when the protein includes multiple domains and when
more than one expression vector is used.
(3) The recombinant proteins are expressed with an affinity tag,
most commonly an N-terminal hexahistidine with a cleavage
site for TEV protease.
(4) Clones producing soluble protein are identified in small
(1 ml) or medium (20–50 ml) scale cultures and IMAC
purification. One or more clones are scaled to 1–10 L, and
the proteins are purified by a sequence of IMAC, gel filtration
(GF) and, when appropriate, cleavage of the tag and re-
purification by IMAC.
(5) Biophysical characterisation of the proteins, including mass
spectrometry (MS), GF, and thermostability analysis.
The entire set of protein domain structures solved by the SGC,
including the sequences of constructs and the full methods, are
continuously updated in the web site [9]; a snapshot list (January
2011) is provided in supplementary table S1. All clones are avail-
able upon request from the SGC or from partner distributors, asDomains produced
(aa range)
Prior status
BAR domain (aa34–236) 67% identity to human Bin1 [21]
(aa1–217) None reported
PEA3, ETS-N-terminal
domain (aa223–326)
Short homology to ets-1
SH3 domain (aa72–138) Structure solved (PDB:3NHN) [22]
FCH: Fes/CIP4 homology
domain (aa254–521)
31% homology in RhoGAP domain
PDZ 2 + 3 (aa254–530) PDZ domain structures solved
by NMR (PDB 2DB5, 2DMZ and 2DAZ)
Homeobox domain
(aa143–211)
Highly homologous to MSX1 in
homeobox
RRM1 (aa1–106) 68% identity to closest PDB
homologue 1X5S
Full-length RCC1 (aa1–421) Structure solved (PDB:1A12) [23]
(aa172–391) None reported
Refolded MyTH4 domain
(aa832–990)
None reported
SH3_SH2_Kinase (aa72–526) Structure solved (PDB:1QCF);
expressed in mammalian cells [24]
domain(aa194–413) Structure solved (aa1–200), PDB:3COO [25]
main (aa27–146) Structure solved (PDB: 1G96). Periplasmic
expression in E. coli [26]
 (aa3443–3553);
4016–4137)
None
55% identical to integrin beta-3 structure
(PDB:3IJE), expressed as complex with ITGAV
in insect or mammalian cells [27,28]
f the number of constructs tested. ‘Domains produced’ indicates the segment of the target
rx and Bacolu refer to clones in the vectors pNIC28-Bsa4, pNIC-CTHF, pNH-TrxT and the
www.elsevier.com/locate/nbt 519
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domains produced at the Oxford SGC has been published [3], also
providing guidelines to construct design. Figure 2 shows the
success rates in expressing human protein domains in E. coli
(Fig. 2a) and in insect cells (Fig. 2b). Figure 2c summarises the
approaches used for production and purification of the proteins
that yielded crystal structures. A clear outcome of the parallel
testing of multiple constructs has been the identification, for a
large fraction of targets, of domains that can be expressed as stable,
soluble proteins in relatively high yields. Once optimal constructs
are identified, purification of most protein domains can be
achieved using standardised procedures. All the truncated proteins
represent intact, independently folded domains; these comprise
enzymatic (e.g. kinase, dehydrogenase, phosphatase), molecular
recognition (e.g. PDZ, 14-3-3, SH2) or regulatory (e.g. RGS)
domains [3].
Processing newly prioritised targets
When facing new proteins that emerge from genetic studies or
pathway analyses, the impact of the accumulated experience of
the SGC and similar organisation can be two-fold. First, many of
the new genes of interest may already have been produced in the
SGC; alternatively, for novel targets, the well-tried methods can beTABLE 3
Genes used in biotinylation experiments
Number Gene Gene family 
1 ARHGEF2 G-protein-GEF 
2 CBPP22 EF hand 
3 CDC42 GTPase-RHO 
4 CENTG1 GTPase-RAS 
5 DIRAS2 GTPase-RAS 
6 DIRAS1 GTPase-RAS 
7 DUSP16 Phosphatase-Du
8 DUSP16 Phosphatase-Du
9 GEM GTPase-RAS 
10 GNAI3 GTPase-Trimeric
11 MAP2K2 (MEK2) Kinase-STE 
12 MAP2K3 (MEK3) Kinase-STE 
13 MAP2K4 (JNKK1) Kinase-STE 
14 MAP2K5 (MEK5) Kinase-STE 
15 MAP2K6 (MEK6) Kinase-STE 
16 MAP2K7 (JNKK2) Kinase-STE 
17 MAPK3 (ERK1) Kinase-CMGC 
18 MAPK6 (ERK3) Kinase-CMGC 
19 MAPK8 (JNK1) Kinase-CMGC 
20 MAPK9 (JNK2) Kinase-CMGC 
21 PAK4 Kinase-STE 
22 PAK7 Kinase-STE 
23 PAK6 Kinase-STE 
24 PPP1R12B Phosphatase-re
A list of the human genes used in the experiments shown in Figs. 3 and 4. The numbering c
produced from the vector pNIC28-Bsa4, which include a His6-tag only. The C-terminal biotin
The column marked Biotin/unmodified summarises the results of test expression of the C-term
medium (Fig. 3 and similar experiments). ‘0’ indicates no effect, ‘–’ indicates a reduction in yie
520 www.elsevier.com/locate/nbtused to rapidly generate and identify constructs that produce
soluble proteins. To test this, we attempted to handle a set of
non-membrane proteins suggested by collaborators, with no con-
sideration of prior work at the SGC or of predicted tractability. The
15 selected proteins were new to us; a few were purified previously
by other groups, while some were not reported to be purified. Table
2 summarises the cloning and testing processes performed on each
of the targets, within a time frame of three months.
In all cases, we have applied our standard construct design and
evaluation principles regardless of prior knowledge; when a pro-
tein structure was known, the designed construct boundaries
closely clustered around the published structural boundaries.
Constructs for cytoplasmic expression were cloned in parallel into
four vector systems [3]: the E. coli vectors pNIC28-Bsa4 (N-terminal
His6 tag), pNIC-CTHF (C-terminal His6 + Flag tag), pNH-TrxT (N-
terminal His6/Thioredoxin tag) and the baculovirus transfer vector
pFB-LIC-Bse (N-terminal His6 tag). Four targets encoding extra-
cellular or secreted domains were expressed in E. coli as fusions to
the bacterial secreted protein OsmY [5]. Equivalent constructs
were cloned into a baculovirus transfer vector, fused to a signal
peptide of baculovirus gp64.
Table 2 represents the results, which are typical of the parallel
approach used in structural genomics. Using just a default vectorMr (kDa) Biotin/unmodified
47.2 –
25.0 0
23.8 N/D
22.0 –
22.1 –
24.9 –
al-Spec 36.6 –
al-Spec 18.7 –
23.8 –
 42.6 0
42.3 0
37.1 –
43.3 N/D
36.0 N/D
35.2 –
42.9 N/D
45.7 N/D
40.2 N/D
44.5 –
46.3 –
66.6 –
38.0 0
77.4 –
gulatory 39.0 0
orresponds to the annotations in the figures. The molecular weights are of the proteins
ylation tag adds 2.6 kDa.
inal tagged proteins, comparing the yield in presence and absence of biotin in the growth
ld in the presence of biotin, and N/D indicates that the yields were too low to compare.
New Biotechnology Volume 29, Number 5  June 2012 RESEARCH PAPER
FIGURE 3
Effect of biotin in culture media on expression of biotin-tagged proteins. The 24 genes listed in Table 3 were cloned into vectors pNIC28-Bsa4 (panels A and B) and
pNIC-Bio3 (panels C and D). 1-ml cultures of each clone were induced in presence (+) or absence () of 50 mM biotin in the culture medium. The recombinant
proteins were extracted and purified by IMAC, resolved by SDS-PAGE gradient gels, and stained with Coomassie blue. The recombinant proteins can be identified
according to the predicted masses listed in Table 3; some proteins show aberrant mobility, possibly due to heterogeneous modification or proteolysis. (Note: the
lanes marked ‘none’ indicate missing clones.)
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FIGURE 4
Effect of the N-terminal tag on protein yields. The 24 genes listed in Table 3 were cloned into vectors with a His6 tag (panels A and B) or a His10 tag (panels C
and D). Each pair of adjacent lanes differ by the absence (0) or presence (B) of a C-terminal biotin tag, which adds 2.6 kDa to the protein mass. In panels A
and B, the genes are cloned into pNIC28-Bsa4 (lanes 0) and pNIC-Bio3 (lanes B). In panels C and D, the genes are cloned into pNIC-H102 (lanes 0) and pNIC-
Bio2 (lanes B). 1-ml cultures of each clone were induced in presence of 100 mM in the culture medium. The recombinant proteins were extracted and
analyzed as in Fig. 3.
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FIGURE 5
Comparison of expression of SH2 domains with (Y-axis) or without (X axis) a C-
terminal biotin acceptor tag. 35 human SH2 domains were cloned into the
vectors pNIC-H102 (no biotin tag) and pNIC-Bio2 (C-terminal biotin tag). Each
of the resulting 70 clones was used in a 1.5-Litre expression culture, in
presence of 50 mM biotin. The proteins were purified and the yields were
measured as described. Each spot represents the yields from one gene in
both vectors, in mg of purified protein/L of culture. The dotted line (x = y) is
overlaid to indicate that, for most proteins, the yield of biotinylated protein is
lower than the corresponding protein lacking the biotin tag.
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the majority of cytoplasmic targets tested. One gene (RCC1) only
yielded substantial levels of soluble expression in E. coli with either
the C-terminal tag vector or a large fusion tag (thioredoxin), and
another (TEX9) was only soluble with the C-terminal tag vector.
Two other genes (PLEKHH1 and the enzymatic domain of HCK)
could only be expressed in bacteria with a thioredoxin tag. The
recently introduced OsmY fusion [5] allowed the production of
secreted domains of SPON1, CST3 and FAT3; the secreted proteins
could be harvested in approximately equal amounts from the
culture supernatants and from the periplasm. One construct
was selected from each gene for large-scale (1–4 L) purification;
all proteins showed well-defined peaks on gel filtration, and were
confirmed by mass spectrometry. Finally, expression of ITGBV
(Integrin b5) was attempted in insect cells as a near full-length
protein, in combination with integrin a5, but the levels were
marginal. This target may require more extensive optimisation
or expression as fragments.
In summary, we have been able to produce soluble domains of
14 out of 15 targets tested, with yields of several milligrams. This,
together with earlier data from the SGC and others, demonstrates
the feasibility of providing soluble domains for the majority of
novel targets emerging from genetic and systematic studies of
disease pathways.
In vivo biotinylation
Biotinylation of the antigen is often the method of choice for
protein immobilisation for selecting and evaluating affinity
reagents. In vitro biotinylation is frequently used, whereby lysine
residues in the antigen are chemically modified. However, bioti-
nylation of a short acceptor peptide in vivo is an attractive method
to achieve site-specific modification without the risk of interfering
with protein folding or function of the antigen. In vivo biotinyla-
tion is achieved by co-expressing the protein of choice (fused to a
biotin acceptor peptide) and the bacterial biotin-protein ligase
(BirA) in the presence of biotin. To investigate factors that affect
the yield and homogeneity of biotinylated proteins, we tested a set
of 24 human proteins using two vector systems. Biotin acceptor
tags were added at the C-termini, and oligohistidine sequences
(cleavable with TEV protease) were added at the N-termini for
protein purification. Based on our sporadic observations, we tested
both hexahistidine (His6) and decahistidine (His10) tags. The latter
could be useful for some applications (e.g. SPR), but may decrease
protein yields because of aggregation.
24 diverse human protein domains (Table 3) were cloned into
each of four vectors, generating combinations of His6 or His10 tags,
with or without biotinylation sites (vectors pNIC-Bio3, pNIC-Bio2,
pNIC28-Bsa4 and pNIC-H102, see Fig. 1). Soluble protein produc-
tion was tested in triplicate small-scale cultures in the presence of
100 mM biotin; the yield of soluble protein was evaluated using
SDS-PAGE of fractions eluted from Ni-NTA beads. In separate
experiments, the clones in the His6 vectors pNIC28-Bsa4 and
pNIC-Bio3 were tested in the absence of biotin or in presence of
50 and 100 mM biotin.
Figure 3 shows a representative experiment, comparing protein
production in absence (lanes marked ‘’) and presence (‘+’) of
50 mg/ml biotin. Panels A and B show expression of protein
domains cloned in pNIC28-Bsa4, lacking a biotinylation signal.In general, the intensity of the stained bands in each pair of lanes
(/+ biotin in the growth medium) is similar. Panels C and D show
expression of protein domains cloned in pNIC-Bio3, which con-
tain a C-terminal biotin acceptor site. Here, the picture is different:
A fraction of clones (e.g. clones 1, 4, 5, 9, 12, 15) show significantly
lower yield (2–7-fold) of protein in the presence of biotin. Further-
more, some clones (e.g. 17, 18) yield very little protein with the C-
terminal tag compared with the untagged protein, regardless of
the biotin concentration in the culture medium. These effects are
protein-specific, as several clones (e.g. 8, 10, 11, 22 and 24) are
indifferent to the presence of biotin. The results of this (and
replicate) experiment(s) are summarised in Table 3.
Figure 4 shows a representative experiment comparing the two
N-terminal purification tags: His6 (panels A and B) and His10
(panels C and D). In each pair of lanes, the lane marked ‘0’ is
the protein lacking the C-terminal biotin tag, and the lane marked
‘B’ is the C-terminal tagged protein. The difference in size between
each pair represents the 2.6 kDa tag (peptide + biotin). Comparing
the recovery of purified proteins from the His6 and His10 vectors
(panels A vs. C and B vs. D), the results are gene-specific. However,
there is a tendency for lower yields of the His10-tagged proteins
relative to the His6-tagged counterpart.
Small-scale experiments provide only a semi-quantitative esti-
mate of protein yields. We tested a separate set of 35 SH2 domains
cloned into pNIC-H102 and pNIC-Bio2, at a production scale of
1.5 L (in the presence of 50 mM biotin). The proteins were purified
using a standard two-step procedure (IMAC and gel filtration), and
the yields were measured. Figure 5 shows the comparison of thewww.elsevier.com/locate/nbt 523
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FIGURE 6
Mass spectrometric (MS) analysis of biotinylated proteins. Three proteins expressed in E. coli from vector pNIC-Bio2 in combination with pCDF-BirA were purified
and analyzed by LC–ESI-MS. The expected masses of the three proteins (including a single biotin modification) are: (a) HADH2: 32,310 Da, (b) RPS6KA2: 44,064 Da,
(c) PTPN1: 40,060 Da. The deconvoluted mass spectra are indicative of homogeneously modified proteins. The observed masses (32,312, 44,067 and 40,062,
respectively) are as expected within 3 Da; the reasons for the small mass deviations are unclear.
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The graph shows the considerable scatter of the results; most of the
points are below the diagonal (x = y; dotted line), illustrating that
the yield of biotinylated proteins is usually lower than that of the
corresponding clone lacking the biotin acceptor peptide. The
average reduction in yield is only 30%, but 6/35 clones tested
showed more than 5-fold reduction in yield. Although low yields
can be overcome by increasing culture volumes, it may be worth
testing in individual cases whether the biotin tag affects the
stability or solubility of the purified protein.
The precise masses of the purified proteins were evaluated using
mass spectrometry (representative results are shown in Fig. 6). For
all proteins expressed with the biotin acceptor tag, >90% of the
purified protein was biotinylated. We could also obtain mass
measurements for the highly expressed proteins purified from
the small-scale cultures. In all cases, fully biotinylated proteins524 www.elsevier.com/locate/nbtwere observed when the culture medium included 50 or 100 mM
biotin. No biotinylation was seen when the medium did not
include added biotin. The lower concentration of biotin is suffi-
cient for full biotinylation of all proteins included in this study;
however, we have encountered a small number of (highly
expressed) proteins where higher concentrations of biotin were
required.
The optimal procedure that emerges from these biotinylation
experiments and other experiments not shown are: (1) Addition of
a biotin acceptor tag can affect protein expression in unpredicted
ways, often leading to reduced yields. (2) Addition of 50 mM biotin
to the culture medium is generally sufficient to achieve full
biotinylation, although special cases of highly expressed genes
may required adding 100 mM or more. (3) A host strain that
expresses BirA as well as rare-codon tRNAs gives optimal, consis-
tent results for eukaryotic genes. (4) As always with protein
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erproduction, individual proteins may require specific optimisation
of the induction, extraction and purification conditions.
Concluding remarks
Earlier studies have shown the synergy between the protein-pro-
ducing capacity of structural biology and high-throughput pro-
duction of affinity reagents [4,20]. In the original studies [4,20], a
set of purified protein domains from the SH2 family was produced,
and recombinant or monoclonal binders to most of them were
obtained within a short time span. The panel of related protein
domains provided an excellent platform for assessing the selectiv-
ity and the binding affinities of the binders.
The present work explores the possibility of extending the anti-
gen space to a wider variety of human proteins, especially those
associate with disease or with signalling networks. The panels of
purified proteins produced through the activity of large-scale struc-
tural biology programs already include >1000 human proteins of
interest. The small pilot study reported here shows that processing
of new proteins to generate soluble domains can be achieved with
high efficiency. Finally, the initial results of transferring previously
expressed proteins to an in vivo biotinylation system show that,
although the protein yields are sometimes lower, it is possible to
routinely achieve complete biotinylation of all proteins tested.
The ability to rapidly provide purified proteins (and, subse-
quently, affinity reagents) from novel genes that emerge from
functional and genetic studies, can provide a major opportunityto understanding the roles of these proteins and their suitability as
targets for clinical intervention.
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